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Genetic screening: Actionable information for epilepsy patients and clinicians 
Screening for epilepsy-related gene variants can lead to effective, personalized treatment plans 
while reducing costs. UK and Danish scientists, led by Deb Pal, King’s College London, evaluated a 
new service within the UK that searches for genetic variants in patients that cause epilepsy. The 
authors assessed the impact of next-generation gene panel tests, as well as the necessary resources 
to make such a service effective. Genetic testing was most effective in patients with seizure onset 
under two years old (21% diagnosed) and yield even higher in neonatal-onset epilepsy (63% 
diagnosed). For many patients with pathogenic variants, the diagnoses allowed for 
recommendations on treatment or enrolment in clinical trials. The researchers found that diagnostic 
delay and financial burden in neonatal epilepsy could be drastically reduced with gene panel testing. 
The scheme was highly rated by users and patients alike. 
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Abstract 44 
We evaluated a new epilepsy genetic diagnostic and counseling service covering a UK population of 3.5 45 
million. We calculated diagnostic yield, estimated clinical impact, and surveyed referring clinicians and 46 
families. We costed alternative investigational pathways for neonatal onset epilepsy. Patients with epilepsy of 47 
unknown aetiology onset < 2years; treatment resistant epilepsy; or familial epilepsy were referred for 48 
counseling and testing. We developed NGS panels, performing clinical interpretation with a multidisciplinary 49 
team. We held an educational workshop for paediatricians and nurses. We sent questionnaires to referring 50 
paediatricians and families. We analysed investigation costs for 16 neonatal epilepsy patients. Of 96 patients, a 51 
genetic diagnosis was made in 34% of patients with seizure onset < 2 years, and 4% > 2 years, with turnaround 52 
time of 21 days. Pathogenic variants were seen in SCN8A, SCN2A, SCN1A, KCNQ2, HNRNPU, GRIN2A, SYNGAP1, 53 
STXBP1, STX1B, CDKL5, CHRNA4, PCDH19 and PIGT. Clinician prediction was poor. Clinicians and families rated 54 
the service highly. In neonates, the cost of investigations could be reduced from £9,362 to £2,838 by 55 
performing gene panel earlier and the median diagnostic delay of 3.43 years reduced to 21 days. Panel testing 56 
for epilepsy has a high yield among children with onset < 2 years, and an appreciable clinical and financial 57 
impact. Parallel gene testing supersedes single gene testing in most early onset cases that do not show a clear 58 
genotype-phenotype correlation. Clinical interpretation of laboratory results, and in-depth discussion of 59 
implications for patients and their families, necessitate multidisciplinary input and skilled genetic counseling.   60 
 61 
Keywords: Next Generation Sequencing; effectiveness; clinical utility; diagnostic yield; genetic counselling; 62 
personalized medicine; health service research; economic. 63 
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Introduction 68 
Genetic testing and counseling for epilepsy is now being incorporated into everyday practice in many parts of 69 
the industrialised world 1. This advance has been driven by rapid discoveries in the aetiology of rare 70 
monogenic epilepsies, and technological developments in next generation resequencing (NGS)2. The 71 
integration of NGS testing into practice is accompanied by several challenges including clinician education, 72 
results interpretation, and counseling for patients and their families 3.  73 
We reflect on our experience of this transformational change from the perspective of a health service 74 
provider, specifically assessing: (a) the effectiveness and utility of NGS testing, (b) the necessary inputs, and (c) 75 
areas where service improvements can be made to facilitate the transition to “Precision” or “Personalised 76 
Medicine”. We also asked specific questions about single vs parallel gene testing pathways based on clinician 77 
predictive ability; the relative diagnostic yield for different age of onset or epilepsy syndrome; what priorities 78 
clinicians and families identify; the resources necessary to provide an effective service, and whether NGS can 79 
save time and money 4,5 using the neonatal epilepsy group as an example. We address these questions in the 80 
context of a review of the initial operation of a UK regional epilepsy genetics service to a population of 81 
approximately 3.5 million. To our knowledge there is limited published data from other specialist epilepsy 82 
genetics services that similarly reviews their own experience6, therefore this study aims to fill a gap in that 83 
respect. However, there are several articles on the utility of genetic testing in epilepsy and published yield 2,7-9. 84 
Our study aims to add to the current literature and, in addition, fill in the gaps in knowledge about how to set 85 
up a tailored epilepsy genetics service, what referring clinicians and patients and families think about such a 86 
service, and the cost saving implications of performing genetic testing.  87 
 88 
Results 89 
Demographics. Ninety-six unrelated eligible patients (55 male) were referred to the service, either through the 90 
specialist outpatient clinic (n=40) or directly for molecular investigation through their paediatrician or 91 
paediatric neurologist. All were consented for gene panel analysis. As this was a new service, many patients 92 
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were tested years after onset or diagnosis, including one adult patient and two post-mortem. We categorized 93 
them broadly into age of onset and syndrome classes (Table 1). Sixty-four percent (49/77) were classified as 94 
drug-resistant 10.  95 
 96 
Identified variants. Seventy-four of our ninety-six patients had previous array Comparative Genomic 97 
Hybridisation (aCGH) performed (77%), of which 16 (22%) had an identified benign chromosomal 98 
rearrangement. The remainder had no detected rearrangement and a normal chromosomal complement. 99 
Patients with pathological findings on the aCGH do not tend to make their way into our clinic. In fact, only 100 
three patients out of forty-four referred for aCGH by one of the three local clinicians we work with were found 101 
to have a pathogenic chromosomal rearrangement by the local laboratory (ViaPath) and were not referred on 102 
to our service: one showing Angelman’s syndrome; one Klinefelter’s syndrome; and one showing 9q34 103 
deletion. However, the match between the epilepsy phenotype and the chromosomal rearrangement is not 104 
conclusive in any of these three cases so none of these can be considered completely “solved”.  105 
 106 
For NGS panel testing, 11 patients were tested on the original CHildhood Epilepsy panel containing 45 genes 107 
(CHE-45); 11 on the CHE-76 (Childhood Epilepsy panel containing 76 genes); 49 on CHE-85 (Childhood Epilepsy 108 
panel containing 85 genes), and 23 on CHE-102 (Childhood Epilepsy panel containing 102 genes); 2 patients 109 
were referred to the epilepsy genetics service with existing positive gene panel results from another provider. 110 
The gene panel itself was designed by the following co-authors: RSM, DKP and HAD. The criteria for including a 111 
gene on the panel were that it should have been reported more than once in patients with monogenic 112 
epilepsies. The selection of genes on the panel was regularly evaluated and updated. The panel included of 113 
targeted capture of all exons and at least 5 base pairs of flanking intronic sequence of the selected genes. 114 
The overall target coverage of the genes on the Amplexa CHE-46 panel was 95– 97%; hence, 3–5% of the 115 
regions were not analyzed, and some variations may have been missed, while the average target coverage for 116 
the larger three panels was 98-99.5%. The regions missed were more or less identical across the different 117 
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samples, i.e. regions difficult to amplify due to high GC content, repeat elements, or regions with homology in 118 
other parts of the genome.  119 
 120 
Amplexa Genetics reporting follows the ACMG guidelines. However, there is an argument that these guidelines 121 
are not very suitable for conditions with variable penetrance (which many types of epilepsy have been shown 122 
to have). As our knowledge and understanding of epilepsy genetics is still limited, they do also report Class II 123 
(benign) variants, and this allows us to monitor them in case our understanding changes in the future. When 124 
we receive a report from Amplexa, we then compare that with our understanding of the phenotype to check 125 
whether this fits with the clinical picture. This often leads us to re-grade classifications of variants reported. If, 126 
however, we are still uncertain, we will request assistance from experienced colleagues in the field. Parental 127 
segregation may also lead to re-classification of variant class if the results fit with the phenotype or family 128 
history e.g. 95% of SCN1A variants causing SMEI will be de novo. Parental segregation was deemed necessary 129 
when a class IV variant (defined as per the ACMG 2015 Guidelines11) or above was identified in the child, or a 130 
Class III variant was identified and it was in a gene that seemed to match with the child’s phenotype and/or 131 
family history, or in genes where de novo variants are usually pathogenic. 132 
61% of patients (n=59) had one or more variants (Single Nucleotide Variants only - SNV) reported: 31 had only 133 
benign variants; 9 had variants of unknown significance (VUS), and 19 had variants judged to be of pathogenic 134 
significance. The average number of any variant, not just pathogenic, increased in line with the expansion in 135 
size of the gene panel (CHE-46: 1.3; CHE-102: 1.8) indicating the additional burden of clinical interpretation 12. 136 
We were constrained in our ability to retest panel negative cases because the testing was done under clinical 137 
auspices and therefore no patient with initial negative results were retested on a larger panel in this study. 138 
This means that the stated diagnostic yields probably underestimate what could have been achieved if 139 
everyone had been tested on the most up to date panel. The average turnaround time for results was 21 140 
working days, less when no variants were seen (18 days) because Sanger validation was not necessary, and 141 
slightly more when parental segregation and new sample collection were necessary.  142 
 143 
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The pipeline used by Amplexa Genetics to establish pathogenicity of variants does indeed resemble other 144 
genetic testing NGS models11-13. The panels used were designed to cover all coding exons and exon-intron 145 
boundaries of the included genes, including an additional 10 bp of the introns. Sequences were aligned to 146 
hg19 using the Torrent Suite (ThermoFisher) and SNPs with a read depth ≥20 and variant allele frequency of 147 
≥0.25 were called using the Strand NGS software. Rare or low frequency variants were evaluated in an 148 
internally developed pipeline. Included in this evaluation were literature and database searches like Human 149 
Gene Mutation Database (HGMD), Exome Aggregation Consortium (ExAC) database, the Genome Aggregation 150 
Database (gnomAD). Synonymous variants and variants in autosomal dominant genes which had been 151 
observed more than 3 times or in homo-/hemizygous state in the ExAC/gnomAD database were excluded in 152 
severe Epileptic Encephalopathy (EE) cases. All variants were submitted to prediction tools – predictions on 153 
protein level were obtained from dbNSFP Functional Predictions and Cores 3.0 database while the variants 154 
were submitted to bioinfomatic software tools e.g. NNSplice and ESEfinder for predictions on transcriptional 155 
level. The ACMG guidelines were applied to the resulting variants11. 156 
Pathogenic variants are listed in Table 3: SCN8A (n=4) and SCN2A (n=3) were the two most commonly 157 
implicated genes. Two pathogenic variants were observed in SCN1A but not in typical SCN1A-associated 158 
Generalised Epilepsy with Febrile Seizures (GEFS) or Dravet syndrome cases. Variants of unknown significance 159 
were detected in GABRA5, SCN8A, CHRNB2, RYR3, HNRNPU, CACNA1A, SPTAN1, PIGA, KCNQ3, SLC2A1, NPRL3 160 
and CHRNA4 (Table 4).  161 
 162 
Variant yield. The yield varied according to age of seizure onset - Table 5 shows results by patient and, if a 163 
patient has several different variants they are classified by their most “serious” ranked variant 164 
(pathogenic>VUS>benign). The 59 patients with at least one variant (benign, VUS and pathogenic included) 165 
had a total of 54 benign variants amongst them (17 patients had more than one benign variant and 6 had one 166 
or more benign variants plus a VUS or pathogenic variant as well); 9 variants of unknown significance; and 20 167 
pathogenic variants (one patient had two variants in two different genes). 12 of the variants were Class 4 and 168 
7 were class 5, as per the ACMG guidelines11. The diagnostic yield, defined as the percentage of cases “solved” 169 
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by NGS panel testing was highest in the neonatal onset epilepsies (63%), intermediate in the remaining first 170 
two years of life (21%), and lowest when onset was later (4%). The diagnostic yield was 23% among drug 171 
resistant cases. Clinicians attempted gene prediction (by informed guesses) in 33 cases, and were correct in 172 
five (15%): SCN1A, PCDH19, GRIN2A, CDKL5, SCN2A 9.  173 
 174 
Impact. In 63% of cases with pathogenic variants, the results had an immediate implication for treatment. 175 
Most involved ion channel subunit genes such as SCN1A, SCN2A, SCN8A, KCNQ2, leading to recommendations 176 
about Na+ blocking antiepileptic drugs in 10 cases. Two cases with acetyl-choline receptor subunit variants 177 
that were suspected phenotype modifiers (CHRNA4, CHRNB2) were offered experimental nicotine therapy 14. 178 
It should be noted that the patient with the CHRNB2 VUS did not have his treatment altered because of this 179 
VUS. However, as we suspected it to be a phenotype modifier, he was offered the chance to try experimental 180 
nicotine therapy as an adjunctive treatment, to see if that had any impact on his seizures. One-quarter of cases 181 
were entered into a registry or research study. The families with pathogenic variants were offered expert 182 
genetic counseling: in six cases (31%) an additional affected relative was diagnosed.  183 
 184 
Workshop and Surveys. 19 paediatricians and epilepsy nurses attended the workshop and all offered 185 
feedback. 100% agreed that the workshop was excellent and they were likely to change their practice going 186 
forward. We received 10 survey responses from families (25% response), and six from clinicians (40%). Both 187 
the outpatient and molecular diagnostic components of the service were rated as good or excellent (100%) by 188 
clinicians. Families also rated our services highly and 100% would recommend to friends and family (Table 6). 189 
 190 
Investigational cost. We retrieved complete records for 16 neonatal epilepsy patients. Total investigation 191 
costs ranged from £5,094 to £15,622, average £9,362, with more than 75% of the costs allocated to 192 
neuroimaging and videoEEG-telemetry. In multiple linear regression, we found statistically significant and 193 
independent correlation only between diagnostic delay and cost of previous genetic tests (p=0.011). 194 
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Prior single gene testing among this sample included Fragile-X (FMR1), Ataxia-Telengectasia (ATM), Niemann-195 
Pick C (NPC1, NPC2), Spinal muscular atrophy (SMN1, SMN2), Prader-Willi syndrome (15q11.2-q13), Myotonic 196 
Dystrophy (DMPK), ARX, atypical Rett syndrome (CDKL5), and Glutaric aciduria Type 1 (GAT1). Because both 197 
MRI and EEG can be performed for disease monitoring as well as diagnosis, we excluded these and focused on 198 
the remaining laboratory analyses performed on blood, urine and cerebrospinal fluid (CSF) samples. We found 199 
that two-thirds of these costs (total average per patient: £2,004) were made up of array CGH and single gene 200 
tests, as well as metabolic investigations and invasive lumbar puncture. The delay between epilepsy onset and 201 
diagnosis ranged from 83 days to 17 years (median 3.4 years). Consequently, we calculated that if all neonatal 202 
epilepsy patients underwent NGS panel testing as part of their first line investigations, their theoretical total 203 
investigational costs would have averaged £2,838, which is £6,524 less (70%) than the actual average cost.  204 
 205 
Discussion 206 
NGS panel testing in epilepsy is largely effective and useful, and has particular strengths for early onset 207 
epilepsies. The high diagnostic yield in the neonatal (63%) and infant (21%) onset groups is unprecedented. 208 
We do not think there is any one answer as to why the yield was so high, however only selecting the most 209 
appropriate patients for testing and having a good panel design are of course very important factors.  210 
There is a significant impact on treatment and risk counselling for the majority of genetically diagnosed cases2. 211 
Families put a high value on exploring the implications of the results for their child and family; and referring 212 
clinicians appreciated the quality of clinical interpretation and rapid turnaround time.  213 
The inputs required are substantial and complex: in our context, they were based on an existing integrated 214 
tertiary and secondary level regional epilepsy service, and relied on an educated referral base to select 215 
appropriate cases, an expert multidisciplinary team for interpreting variants with clinical features, and the 216 
skills of a specialized genetic counselor to translate findings into tangible benefits for families.  217 
There is also a potential for huge reduction in investigation burden, cost and delay, taking into account the 218 
priorities of users and referrers.  219 
 220 
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1. Utility and Effectiveness.  221 
1.1 Diagnostic Yield and Clinical Impact. Yields of 10-48.5% have been reported from diagnostic NGS panels 222 
consisting of 36-265 target epilepsy genes 7,9,15-20, with a higher diagnostic yield in children under 2 years at 223 
seizure onset. We found patients with pathogenic variants in the most common epilepsy genes SCN8A (n=4), 224 
SCN2A (n=3), SCN1A (n=2), KCNQ2 (n=2) and STXBP1, GRIN2A, CHRNA4 (n=1 each), accounting for 70% of all 225 
presumed disease-causing variants (Table 3). In all living cases involving Na or K channel mutations, 226 
recommendations or changes were made to antiepileptic medications (AEDs). 9% of cases were entered into a 227 
clinical trial; 26% of cases were entered into a phenotype registry or study awaiting future trials, and families 228 
were introduced to online patient groups. Additionally, one quarter of patients had another relative diagnosed 229 
following their diagnosis. The rapid turnaround time of 21 working days (14 days for urgent cases) means 230 
interventions could be started in sufficient time to theoretically modify disease course or prevent 231 
complications, although the evidence base for such therapies is yet to be established 21. In addition, we found 232 
presumed pathogenic variants in epilepsy genes that have not been well characterized including HNRNPU, and 233 
the recessive PIGT (homozygous). 8 of the 20 pathogenic variants have previously been published 7,8,15,22-32 a 234 
further 3 are listed in ClinVar (Table 3); while 9 are novel.  235 
 236 
1.2 Single vs parallel gene testing. The philosophy of parallel testing or “gene-first”, in patients where a 237 
genetic cause is suspected but there is extensive genetic heterogeneity, is vindicated by clinicians’ limited 238 
ability to predict results, and by some remarkable surprises. Clinician prediction was not often attempted and 239 
we suspect this is because of the extreme genetic heterogeneity, pleiotropy, reduced penetrance and variable 240 
expression in infantile onset epilepsies, these factors providing the rationale for parallel gene testing 33,34. The 241 
cases in which prediction was attempted reflect examples where there is better known genotype-phenotype 242 
correlation. There are for example, some more specific clinical features that are characteristic of one, or a 243 
handful, of genes: clustering of febrile seizures (PCDH19); temperature sensitivity (SCN1A); etc. We discuss 244 
two case examples involving patients with pathogenic mutation in these genes in the discussion section.  245 
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Still there were many surprises as evidenced by the poor prediction rate. The full phenotypic spectra of many 246 
epilepsy genes are currently being reported in the literature; as part of our continuing clinician education for 247 
referring clinicians, we aim to disseminate this new knowledge to ensure that patients are accurately selected 248 
for genetic testing. The following three cases deserve discussion because they demonstrate the strong clinical 249 
foundation necessary for genetic testing in epilepsy.  250 
 251 
The first was a seven-year-old child with early-onset (3 years) drug-resistant absence seizures preceded by 252 
multiple febrile seizures; her mother noted the absences were sensitive to high temperature. Her father had 253 
drug-responsive juvenile onset absence epilepsy. aCGH showed a paternally inherited 15q13.3 deletion, which 254 
explained the familial susceptibility to absence seizures, but not the daughter’s early age of onset, drug 255 
resistance, febrile seizures or heat sensitivity. Gene panel testing then revealed a de novo mutation in SCN1A, 256 
p.Arg1648His (Table 3).  257 
 258 
The second had an onset of Lennox-Gastaut like symptoms in the first year of life, with severe learning 259 
difficulties including developmental regression of language and motor function at the age of three. He had a 260 
pattern of nocturnal motor seizures clustering over several days, repeating three times per month, and was 261 
drug-resistant. NGS panel results showed pathogenic variants in HNRNPU (de novo) and CHRNA4 (inherited); 262 
the former explaining his overall phenotype, the second explaining his clustering nocturnal motor seizures. A 263 
trial of transdermal nicotine significantly reduced his nocturnal motor seizures and improved his daytime 264 
communication and functioning 14. Both this case and the SCN1A case exemplify how “second hits” can modify 265 
a seizure phenotype and also act as a focus for therapeutic modulation.  266 
 267 
The third case had severe clusters of infantile convulsions continuing for 48-72 hours and recurring every few 268 
months with intercurrent febrile illness; at age 11 years he became seizure free on levetiracetam and now 269 
attends college. His clinical features resembled the seizure phenotype described in Epilepsy with Mental 270 
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Retardation Limited to Females 35. NGS panel testing surprisingly revealed a mosaic heterozygous mutation in 271 
PCDH19. There are very few reported cases in males, and the genetic mechanism remains obscure 36.  272 
 273 
In the older age group (seizure onset >2 years), the diagnostic yield was relatively low (4%). One reason is that 274 
far fewer genes have been discovered in later onset epilepsies, and this should prompt us towards more 275 
concerted efforts in collaborative gene discovery, especially in the focal epilepsies. However, it is likely that 276 
many of these later-onset epilepsies have a more complex aetiology and so even when we discover some of 277 
the associated genes, their impact on disease development will probably be modest and show wide variability 278 
of penetrance and expression amongst affected individuals.  279 
 280 
Genes for autosomal dominant sleep-related hypermotor epilepsy (ADSHE), although among the first 281 
discovered (CHRNA4, CHRNB2, CHRNA2, KCNT1, DEPDC5, CRH, PRIMA1) still only explain approximately 10% of 282 
cases 37. Unfortunately, none of our five tested patients carried a causative mutation, suggesting that genetic 283 
testing is not cost-effective in differentiating nocturnal motor phenomena in adolescents. Only recently, new 284 
genes for familial focal epilepsy (FFE) have been reported from the GATOR1 pathway (DEPDC5, NPRL2, NPRL3) 285 
and these were missing from earlier versions of the gene panel CHE-46, CHE-76, CHE-85). While we speculate 286 
that some of our FFE patients might have tested positive, we note the low (0.8-12%) current yield in sporadic 287 
and FFE cases 38.  288 
 289 
We also noted the low yield for children with infantile or epileptic spasms. Infantile spasms are aetiologically 290 
heterogeneous: tuberous sclerosis is the most common single cause, followed by hypoxic-ischaemic injury, 291 
stroke and brain malformations, and 70% of cases have abnormal MR imaging 39. In a recent study of 44 292 
unsolved Infantile Seizures (IS) cases, 7% had a de novo chromosomal rearrangement, and pathogenic 293 
mutations were revealed by trio exome sequencing in 28% of the remainder, suggesting that the diagnostic 294 
yield can be significant in fully investigated unsolved cases 40. Among our nine unsolved cases, a complete 295 
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imaging, cytogenetic and metabolic screen had only been completed in one, suggesting room for better 296 
workup of these cases prior to NGS panel testing.  297 
 298 
2. Necessary inputs 299 
2.1 Clinical interpretation. Variant interpretation is not always straightforward, and requires close 300 
cooperation between molecular geneticist, bioinformatician, neurologist and genetic counsellor. We dealt 301 
with a large volume of benign (n=54) or VUS (n=11), which represents a substantial burden for clinical 302 
interpretation as well as a source of uncertainty for families. VUS arise for a number of reasons e.g. 303 
inadequate bioinformatic prediction, lack of functional data, missing segregation, or incomplete knowledge of 304 
genotype-phenotype correlation. In this scenario, segregation information on a novel variant only contributes 305 
to diagnostic certainty when there is confidence about the bioinformatic prediction and the associated 306 
epilepsy phenotype. If the evidence is scant, then proving that the change is de novo, or segregates with 307 
disease in an affected parent will, in reality, make very little difference to the patient or family until further 308 
evidence establishes the VUS as likely pathogenic, or benign. Without expert interpretation, clinicians may be 309 
vulnerable to pitfalls such as over-interpreting variants as mutations or vice-versa 41, and wrongly assigning 310 
pathogenicity to heterozygous variants in recessive conditions.  311 
 312 
2.2 Clinician education and health structure.  Clinicians who understand the benefits and limitations of the 313 
service are able to offer it most effectively to the right patients. Our educational workshop was very useful in 314 
this regard, and most referrals that we received from workshop participants were appropriate and properly 315 
worked up beforehand. Without this hierarchical structure, there is the possibility of bypassing guidelines on 316 
investigation and wasting resources. However, clinical education is an ongoing process and continuing 317 
feedback on outcomes and beneficial impacts are probably necessary to sustain and grow referrals and 318 
appropriate NGS requests. 319 
 320 
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2.3 Genetic counseling. Despite universal access to the internet, many families have limited understanding of 321 
the principles of human genetics and require clear and relevant information, relayed in the context of their 322 
own situation before they can make an informed decision about genetic testing. Genetic counseling is the 323 
process of helping people understand and adapt to the medical, psychological, and familial implications of 324 
genetic contributions to disease42. The genetic counselor is therefore ideally placed to discuss with the family: 325 
facilitating adaptation to their child’s condition, discussing the process and implications of genetic testing, as 326 
well as promoting informed choices, for now and in the future (e.g. family planning). A large proportion of 327 
genetic epilepsies are as a result of de novo mutations, and so cascade testing for the wider family is often not 328 
necessary. However, as germline mosaicism is now thought to be more common than it was originally,43 the 329 
possibility of prenatal testing in any future pregnancies is always discussed. 330 
 331 
3. Re-engineering services for precision medicine  332 
3.1 Clinician and Family Feedback. Clinicians valued the new specialist service, perceiving it helpful for 333 
diagnosis, management and counseling, and 50% believed it had saved additional investigations. Referrals 334 
increased over the course of the study, indicating an unmet need in the population. Families also found the 335 
experience of genetic counseling and testing helpful, regardless of whether their child’s case was solved or 336 
not. This feedback points to the need for informed and unhurried discussion around genetic testing, 337 
something that cannot be currently achieved in the current constraints of a general neurology clinic.  338 
3.2 Cost saving. Clinician perceptions of cost-saving are supported by the analysis of neonatal epilepsy data, 339 
showing that investigation costs could be reduced by two-thirds by ordering an NGS panel earlier in the 340 
pathway, which has been noted before 2,4,5. This might also reduce the median diagnostic delay from 3.43 341 
years to 21 days and feasibly allow the early use of disease-modifying drugs. However, true cost-savings are 342 
likely to be less than the theoretical and would need to be calculated using a prospective study design, 343 
preferably with a non-NGS tested concurrent control group. Such calculations may need to be repeated as 344 
technology evolves. Nevertheless, guideline revision requires consensus and commitment from multiple 345 
organizational stakeholders.  346 
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Limitations. While a prospective design has many advantages in terms of selection bias, there are a couple of 347 
limitations of this study. First, because our clinical pathway separates children with primary epilepsy from all 348 
children with early-onset seizures, and requires a routine workup to exclude lesional and some metabolic 349 
causes as well as excluding single gene testing for SCN1A and SLC2A1, the results may not be generalizable to 350 
other health care contexts. Second, our diagnostic yield concealed some variability because of the evolution of 351 
the gene panel over the period of study, reflecting the fast pace of gene discovery – this might have led to 352 
some under-diagnosis of patients using earlier panels.  353 
 354 
Methods 355 
Ethics. a.) methods were performed in accordance with relevant regulations and guidelines and b.) methods 356 
were approved by The Great Ormond Street Hospital/Institute of Child Health Research Ethics Committee 357 
(reference number: 09/H0713/76). 358 
 359 
Population. We collected prospective data related to genetic testing on 96 patients referred to the King’s 360 
Health Partners epilepsy genetics service for molecular diagnostic testing, between November 2014 and 361 
September 2016. The service is provided to the southeast region of England, a population of approximately 3.5 362 
million including the south-east of London. The region includes two teaching hospitals with tertiary paediatric 363 
neurology departments (King’s College Hospital NHS Trust and Evelina London Children’s Hospital) and eleven 364 
district general hospitals in which there is a general paediatrician with a special interest in epilepsy. Medical 365 
services are state-run and organized through a regional clinical network with common management guidelines 366 
for epilepsy 44. Patients are seen first at their district general hospital before being referred, if appropriate, for 367 
a tertiary specialist opinion either at one of the two tertiary centres or in a regional specialist epilepsy clinic.  368 
The epilepsy genetics service comprises two components: a specialist clinic run by a paediatric epileptologist 369 
with a research interest in genetics (DKP), a genetic counselor (SO) and clinical fellow (ST, RR); and a molecular 370 
genetic diagnostic service using an NGS epilepsy panel (LHGL, QH, HAD), with clinical interpretation by the 371 
whole team. 372 
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Pathway. In the absence of consensus guidelines, we considered patients suitable for genetic testing with 373 
either early-onset (<2 years) epilepsy, treatment resistant epilepsy of unknown cause, or familial epilepsy 374 
where the genetic cause was unknown. Two of our patients sadly died during the testing process. As a rule, we 375 
only considered patients with epilepsy as their primary diagnosis, rather than patients with intellectual 376 
disability (ID) or autism (ASD) who had seizures as part of their phenotype. This is because our service is part of 377 
the epilepsy service, whereas patients with primary ID or ASD who also have seizures do not usually use our 378 
pathway, unless they have a relevant family history. Patients followed one of three pathways for genetic 379 
testing: either being seen (i) in the specialist epilepsy genetic clinic, as above (n=40); (ii) by a paediatric 380 
neurologist (n=7) or paediatric epileptologist (n=37) at one of the two tertiary centres; or (iii) seen by a general 381 
paediatrician (n=12) with a special interest in epilepsy at a district general hospital, with referrals made in 382 
discussion with their linked paediatric epileptologist. Patients were recommended to have completed routine 383 
aetiological investigations as per regional guidelines (EEG, MRI, metabolic as necessary), and the clinician was 384 
asked to complete a proforma summarizing the electroclinical phenotype, epilepsy syndrome, age at seizure 385 
onset, drug response, results of previous investigations, and clinical prediction of candidate gene. We collected 386 
aCGH data in cases where it had been performed. Children with suspected typical Dravet Syndrome (OMIM 387 
607208) or Glut-1 Deficiency syndromes (OMIM 606777) undergo single gene testing and were not included 388 
here; patients with brain malformations are tested on a separate gene panel and also not discussed here. 389 
 390 
At the outpatient visit, we spent approximately one hour with each new patient. The paediatric epileptologist 391 
and genetic counsellor took a detailed clinical and genetic history and performed a neurological examination 392 
on the affected child.  Patients were operationally categorized into broad epilepsy syndromes (Table 1) 393 
because many did not fit into the International League Against Epilepsy (ILAE) classification of epilepsy 394 
syndromes 45. The genetic counselor then discussed the possibility of NGS panel testing, and if the family were 395 
interested, proceeded to explain: the process; benefits and limitations; potential outcomes and what they 396 
might mean; discussed any issues of concern that might arise around results, obtained written informed 397 
consent (using the appended consent form) prior to the start of this study, and planned for follow-up.  398 
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Education. We held a half-day educational workshop aimed at regional paediatricians and epilepsy nurses, to 399 
discuss which patients were suitable for testing, which test to choose and how to obtain informed consent.  400 
We designed the educational workshops along evidence-based lines for effective learning, using case-based 401 
simulations in small groups46-48. After the workshop, attendees gave anonymous feedback indicating that 100% 402 
of them were “likely” or “very likely” to change their practice. We circulated proposed guidelines for genetic 403 
testing to the group which were agreed in consensus. Following this, in actual practice we have seen the 404 
number of referrals increase and that most referrals meet our published guidelines. Furthermore, the number 405 
of new referrers has increased and as we provide email feedback to every referrer, appropriateness is also 406 
improving amongst new referrers. Additionally, we posted separate information for clinicians and families on 407 
our website www.childhood-epilepsy.org. 408 
 409 
Gene Panel. We used the Amplexa Genetics epilepsy gene panel CHE-46 (46 epilepsy genes) at the start of the 410 
service7, which was updated to CHE-76, CHE-85 and CHE-102 during the study period in light of new gene 411 
discoveries (by DKP, RM, HAD), (Table 2). To identify putative disease-causing variants, we performed targeted 412 
NGS of 46-102 epilepsy genes in four successive panels (January 2014 – January 2016). The criteria for 413 
including a gene on the panel were that it should have been reported more than once in patients with 414 
monogenic epilepsies. The genes included on the CHE-46 panel were: ALDH7A1, ALG13, ARHGEF9, CACNA1A, 415 
CDKL5, CHD2, CPA6, DEPDC5, DNM1, GABRA1, GABBR1, GABBR2, GABRB3, GABRD, GABRG2, GNAO1, GRIN1, 416 
GRIN2A, GRIN2B, HCN1, HDAC4, HNRNPU, IQSEQ2, KCNA2, KCNQ2, KCNQ3, KCNT1, KCTD7, LGI1, MBD5, 417 
PCDH19, PLCB1, PNPO, PRRT2, SCN1A, SCN1B, SCN2A, SCN8A, SLC25A22, SLC2A1, SLC35A3, SPTAN1, STX1B, 418 
STXBP1, SYNGAP1, and TBC1D24; additionally for CHE-76: ADSL, ATP1A2, ATP1A3, ATRX, CHRNA2, CHRNA4, 419 
CHRNB2, GABRA5, GAMT, GATM, MECP2, MEF2C, MTOR, PIGA, PIK3AP1, PNKP, POLG, PURA, RYR3, SLC25A2, 420 
SLC6A1, SLC6A8, SLC9A6, SMARCA2, TCF4, UBE3A; and additionally for CHE-85:  CLCN2, CNKRS2, FASN, FOXG1, 421 
HDAC4, HNRNPU, HUWE1, KCNH5, KCTD7, MBD5, PIGO, PIGT, RELN, SIK1, SLC13A5, SLC35A2, SLC35A3, 422 
SLC6A8, SLC9A6, ZDHHC9; and for CHE-102: CACNB4, CUX2, EEF1A2, GRIN2D, KANK1, KCNB1, KCNMA1, 423 
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KIAA2022, NPRL2, NPRL3, PIK3R2, ST3GAL3, SZT2, WWOX. aCGH, where performed, was conducted using an 424 
oligonucleotide array with ~60 000 probes across the genome. Paternity testing was not performed. 425 
 426 
Sample Preparation. Genomic DNA was extracted from blood using standard methods. For the CHE-45, panel 427 
libraries were prepared from 15 ng of template DNA using the Ion AmpliSeq library 2.0 kit and custom primers 428 
following the manufacturer’s instructions (ThermoFisher Scientific)7. The CHE-76, CHE-85 and CHE-102 panel 429 
libraries were prepared from 1000 ng template DNA, Agilent SureSelect target enrichment (Agilent 430 
technologies) and KAPA library preparation kit (KAPA Biosystems) following manufacturer’s instructions. The 431 
library DNA was clonally amplified onto the Ion Spheres Particles (ISPs) by emulsion PCR using an Ion 432 
OneTouch 2 system and the Ion PGM Template OT2 200 kit (ThermoFisher Scientific). ISPs were sequenced on 433 
an Ion PGM sequencer using an Ion 314, Ion 316 or Ion 318 chip and the Ion PGM 200 Sequencing kit as per 434 
the manufacturer’s instructions (ThermoFisher Scientific).  435 
 436 
Bioinformatics. Sequences were mapped to hg19 in the Torrent suite software (ThermoFisher Scientific) and 437 
variant calling was achieved in the Strand NGS software (Avadis) with a minimum of 20-fold read depth. 438 
Common SNPs with an allele frequency ≥2% and SNPs observed in more than 2 samples for each analyzed 439 
sample batch were filtered out. Genetic nonsynonymous/splice site variants were evaluated through database 440 
searches: dbSNP, Exome Variant Server, the Exome Aggregation Consortium database (ExAC), the Genome 441 
Aggregation Database (gnomAD) and HGMD Professional. Missense variants were also submitted to prediction 442 
softwares such as SIFT and PolyPhen-2, while splice site variants were evaluated by NNSPlice and Splicesite 443 
finder. Variants analyzed under a dominant inheritance model that were observed more than 10 times in ExAC 444 
were considered too common as monogenic causes. Potentially pathogenic variants were validated through 445 
conventional Sanger sequencing, and, if possible, parents were included for segregation analysis when 446 
indicated.  447 
 448 
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Criteria for Assessing Pathogenicity of Rare Variants. We share the brief clinical summary of the patient with 449 
the laboratory to aid genotype-phenotype correlation; subsequently we interpret the gene panel report in 450 
detailed clinical context at a monthly multidisciplinary meeting including epileptologists (EH, REW, KL, DKP), a 451 
clinical neurophysiologist (SG) and genetic counselor (SO). We also consulted bioinformatics databases, patient 452 
registries, expert colleagues and published literature. Laboratory reported variants categorized by the ACMG 453 
system 11 were then (re-)classified by us as either benign variants, VUS, or pathogenic variants for the purposes 454 
of genetic counselling. For predicted possibly damaging variants where segregation analysis could be 455 
performed, we required the variant to meet one of the following criteria to constitute a likely pathogenic 456 
variant: de novo in early-onset severe epilepsy syndromes, segregation with the disorder, inheritance from an 457 
unaffected parent but previously reported in other families with the same phenotype and incomplete 458 
penetrance, or adherence to a recessive X-linked or parent-of-origin mode of inheritance.  459 
 460 
Result feedback. We offered either a telephone or face-to-face consultation to the family, followed up with a 461 
written summary of the discussions in a letter.  462 
 463 
Opinion survey. We solicited the views of all 40 families through an anonymous 16-item questionnaire 464 
available as paper copy or web version (www.surveymonkey.com). The questionnaire covered three main 465 
topics of quality, impact and perceived value, and was formulated with the assistance of the Head of Patient 466 
Experience at one of the tertiary centres. We also sent an email link to a 10-item anonymous 467 
(www.surveymonkey.com) questionnaire to all 15 clinicians who had referred patients to the epilepsy genetics 468 
service (questions were adapted from a longer survey used in the evaluation of SCN1A testing 6). 469 
 470 
Investigational cost.  We searched electronic patient records to generate a list and timing of all investigations 471 
ordered in the neonatal epilepsy group; then matched these against 2017 hospital tariffs, separating them into 472 
categories of neuroimaging; EEG; routine blood tests; metabolic investigations of blood, urine and CSF; tissue 473 
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biopsy; array CGH and karyotype; single gene tests; and NGS panel. We assessed the independent association 474 
of imaging, EEG, metabolic and genetic tests with diagnostic delay in days using multiple linear regression. 475 
 476 
Data Availability. All supporting data can be found as presented in this paper. 477 
 478 
Conclusion. NGS-based genetic testing has high clinical utility in children with epilepsy onset before two years 479 
or in drug-resistant or familial cases. The impacts are numerous and range from treatment change to risk 480 
counseling, and potential recruitment to clinical trials as new experimental therapies become available. A 481 
successful service requires strong engagement from secondary health care providers, an existing framework 482 
for specialist referral and investigation, substantial collaboration between clinicians and scientists for variant 483 
interpretation, as well as expertise in genetic counseling and flexibility in communicating with and meeting the 484 
evolving needs of families. To make the best of any innovation in medicine, health care organisations need to 485 
be open to change and reconfiguration of resources to benefit patients and their families.  486 
 487 
Acknowledgements. We would like to thank all the children and families that were involved in this study, as 488 
well as the members of the South-East Thames Paediatric Epilepsy Group (SETPEG) for their attendance at our 489 
Education Day, and their feedback. We would also like to thank the Head of Patient Experience, Sarah Allen, at 490 
Guys and St Thomas’s Hospital for her help with our patient satisfaction questionnaire. Finally, we would like 491 
to thank all our referring clinicians: Dr. Elaine Hughes, Dr. Ruth Williams, Dr. Karine Lascelles, Dr. Katherine 492 
Anderson, Dr. Ming Lim, Prof. Paul Gringras, Dr. Rajesh Gupta, Dr. Nikil Sudarsan, Dr. Vasantha Gowda, Dr. 493 
Darshan Das, Dr. Lyvia Dabydeen and Dr. David McCormick. 494 
 495 
Competing Interests. Stephanie Oates is part funded by Amplexa Genetics. 496 
 497 
Contributions.  498 
Stephanie Oates: writer and co-editor of paper; formulated, sent out and collated data from questionnaires. 499 
 20
Dr Shan Tang: phenotyping of patients and co-editor of paper 500 
Dr Richard Rosch: phenotyping of patients and gave comments on the paper 501 
Rosalie Lear: economic analysis 502 
Dr Elaine Hughes: phenotyping of patients and gave comments on the paper 503 
Dr Ruth Williams: phenotyping of patients and gave comments on the paper 504 
Dr Karine Lascelles: phenotyping of patients and gave comments on the paper 505 
Line HG Larsen: DNA extraction, NGS panel testing, Sanger Sequencing, and bioinformatic analysis 506 
Qin Hao: DNA extraction, NGS panel testing, Sanger Sequencing, and bioinformatic analysis  507 
Dr Hans Atli Dahl: bioinformatic analysis and gave comments on the paper 508 
Dr Rikke S Møller: clinical interpretation and gave comments on the paper 509 
Professor Deb Pal: Guarantor, and assisted with writing and editing of the paper 510 
  511 
Funding Sources. This work was supported by grants from the Canadian Institutes of Health Research 512 
(201503MOP-342469, DKP); European Union Programme of the Seventh Framework Programme Development 513 
of Strategies for Innovative Research to improve diagnosis, prevention and treatment in children with difficult 514 
to treat Epilepsy, “DESIRE” (602531, DKP); National Institute for Health Research (DKP); Medical Research 515 
Council (DKP); Waterloo Foundation (DKP); Charles Sykes Epilepsy Research Trust (DKP); NIHR Specialist 516 
Biomedical Research Centre for Mental Health of South London and Maudsley NHS Foundation Trust (DKP). 517 
 518 
 519 
 520 
 521 
 522 
 523 
 524 
49 525 
 21
References 526 
1 Pal, D. K., Pong, A. W. & Chung, W. K. Genetic evaluation and counseling for epilepsy. Nat 527 
Rev Neurol 6, 445-453, doi:10.1038/nrneurol.2010.92 (2010). 528 
2 Berg, A. T. et al. Early-Life Epilepsies and the Emerging Role of Genetic Testing. JAMA 529 
Pediatr, doi:10.1001/jamapediatrics.2017.1743 (2017). 530 
3 Poduri, A., Sheidley, B. R., Shostak, S. & Ottman, R. Genetic testing in the epilepsies-531 
developments and dilemmas. Nat Rev Neurol 10, 293-299, doi:10.1038/nrneurol.2014.60 532 
(2014). 533 
4 Joshi, C. et al. Reducing the Cost of the Diagnostic Odyssey in Early Onset Epileptic 534 
Encephalopathies. BioMed research international 2016, 6421039, doi:10.1155/2016/6421039 535 
(2016). 536 
5 Tan, T. Y. et al. Diagnostic Impact and Cost-effectiveness of Whole-Exome Sequencing for 537 
Ambulant Children With Suspected Monogenic Conditions. JAMA Pediatr, 538 
doi:10.1001/jamapediatrics.2017.1755 (2017). 539 
6 Brunklaus, A. et al. The clinical utility of an SCN1A genetic diagnosis in infantile-onset 540 
epilepsy. Dev Med Child Neurol 55, 154-161, doi:10.1111/dmcn.12030 (2013). 541 
7 Møller, R. S. et al. Gene Panel Testing in Epileptic Encephalopathies and Familial Epilepsies. 542 
Mol Syndromol, doi:10.1159/000448369 (2016). 543 
8 Butler, K. M. et al. De novo and inherited SCN8A epilepsy mutations detected by gene panel 544 
analysis. Epilepsy Res 129, 17-25, doi:10.1016/j.eplepsyres.2016.11.002 (2017). 545 
9 Trump, N. et al. Improving diagnosis and broadening the phenotypes in early-onset seizure and 546 
severe developmental delay disorders through gene panel analysis. Journal of medical genetics 547 
53, 310-317, doi:10.1136/jmedgenet-2015-103263 (2016). 548 
10 Kwan, P. et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task 549 
Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51, 1069-1077, 550 
doi:10.1111/j.1528-1167.2009.02397.x (2010). 551 
11 Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint 552 
consensus recommendation of the American College of Medical Genetics and Genomics and 553 
the Association for Molecular Pathology. Genetics in medicine : official journal of the 554 
American College of Medical Genetics 17, 405-424, doi:10.1038/gim.2015.30 (2015). 555 
12 Eilbeck, K., Quinlan, A. & Yandell, M. Settling the score: variant prioritization and Mendelian 556 
disease. Nat Rev Genet 18, 599-612, doi:10.1038/nrg.2017.52 (2017). 557 
13 Muzzey, D., Evans, E. A. & Lieber, C. Understanding the Basics of NGS: From Mechanism to 558 
Variant Calling. Curr Genet Med Rep 3, 158-165, doi:10.1007/s40142-015-0076-8 (2015). 559 
14 Brodtkorb, E. & Picard, F. Tobacco habits modulate autosomal dominant nocturnal frontal lobe 560 
epilepsy. Epilepsy Behav 9, 515-520, doi:10.1016/j.yebeh.2006.07.008 (2006). 561 
15 Lemke, J. R. et al. Targeted next generation sequencing as a diagnostic tool in epileptic 562 
disorders. Epilepsia 53, 1387-1398, doi:10.1111/j.1528-1167.2012.03516.x (2012). 563 
16 Carvill, G. L. et al. Targeted resequencing in epileptic encephalopathies identifies de novo 564 
mutations in CHD2 and SYNGAP1. Nat Genet 45, 825-830, doi:10.1038/ng.2646 (2013). 565 
17 Kodera, H. et al. Targeted capture and sequencing for detection of mutations causing early 566 
onset epileptic encephalopathy. Epilepsia 54, 1262-1269, doi:10.1111/epi.12203 (2013). 567 
18 Wang, J., Gotway, G., Pascual, J. M. & Park, J. Y. Diagnostic yield of clinical next-generation 568 
sequencing panels for epilepsy. JAMA neurology 71, 650-651, 569 
doi:10.1001/jamaneurol.2014.405 (2014). 570 
19 Della Mina, E. et al. Improving molecular diagnosis in epilepsy by a dedicated high-throughput 571 
sequencing platform. European journal of human genetics : EJHG 23, 354-362, 572 
doi:10.1038/ejhg.2014.92 (2015). 573 
 22
20 Mercimek-Mahmutoglu, S. et al. Diagnostic yield of genetic testing in epileptic 574 
encephalopathy in childhood. Epilepsia 56, 707-716, doi:10.1111/epi.12954 (2015). 575 
21 Chapman, K. E., Specchio, N., Shinnar, S. & Holmes, G. L. Seizing control of epileptic activity 576 
can improve outcome. Epilepsia 56, 1482-1485, doi:10.1111/epi.13109 (2015). 577 
22 Vaher, U. et al. De novo SCN8A mutation identified by whole-exome sequencing in a boy 578 
with neonatal epileptic encephalopathy, multiple congenital anomalies, and movement 579 
disorders. J Child Neurol 29, NP202-206, doi:10.1177/0883073813511300 (2014). 580 
23 Singh, R., Jayapal, S., Goyal, S., Jungbluth, H. & Lascelles, K. Early-onset movement disorder 581 
and epileptic encephalopathy due to de novo dominant SCN8A mutation. Seizure 26, 69-71, 582 
doi:10.1016/j.seizure.2015.01.017 (2015). 583 
24 Larsen, J. et al. The phenotypic spectrum of SCN8A encephalopathy. Neurology 84, 480-489, 584 
doi:10.1212/WNL.0000000000001211 (2015). 585 
25 Anand, G. et al. Autosomal dominant SCN8A mutation with an unusually mild phenotype. 586 
European journal of paediatric neurology : EJPN : official journal of the European Paediatric 587 
Neurology Society 20, 761-765, doi:10.1016/j.ejpn.2016.04.015 (2016). 588 
26 Parrini, E. et al. Diagnostic Targeted Resequencing in 349 Patients with Drug-Resistant 589 
Pediatric Epilepsies Identifies Causative Mutations in 30 Different Genes. Human mutation 38, 590 
216-225, doi:10.1002/humu.23149 (2017). 591 
27 Wagnon, J. L. & Meisler, M. H. Recurrent and Non-Recurrent Mutations of SCN8A in 592 
Epileptic Encephalopathy. Frontiers in neurology 6, 104, doi:10.3389/fneur.2015.00104 593 
(2015). 594 
28 Zara, F. et al. Genetic testing in benign familial epilepsies of the first year of life: clinical and 595 
diagnostic significance. Epilepsia 54, 425-436, doi:10.1111/epi.12089 (2013). 596 
29 Weckhuysen, S. et al. KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic 597 
encephalopathy. Ann Neurol 71, 15-25, doi:10.1002/ana.22644 (2012). 598 
30 Depienne, C. et al. Genetic and phenotypic dissection of 1q43q44 microdeletion syndrome and 599 
neurodevelopmental phenotypes associated with mutations in ZBTB18 and HNRNPU. Hum 600 
Genet 136, 463-479, doi:10.1007/s00439-017-1772-0 (2017). 601 
31 Lemke, J. R. et al. Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. 602 
Nat Genet 45, 1067-1072, doi:10.1038/ng.2728 (2013). 603 
32 von Stulpnagel, C. et al. Epilepsy in patients with GRIN2A alterations: Genetics, 604 
neurodevelopment, epileptic phenotype and response to anticonvulsive drugs. European 605 
journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology 606 
Society 21, 530-541, doi:10.1016/j.ejpn.2017.01.001 (2017). 607 
33 Grayton, H. M., Fernandes, C., Rujescu, D. & Collier, D. A. Copy number variations in 608 
neurodevelopmental disorders. Prog Neurobiol 99, 81-91, 609 
doi:10.1016/j.pneurobio.2012.07.005 (2012). 610 
34 Parker, L., Howlett, I. C., Rusan, Z. M. & Tanouye, M. A. Seizure and epilepsy: studies of 611 
seizure disorders in Drosophila. Int Rev Neurobiol 99, 1-21, doi:10.1016/B978-0-12-387003-612 
2.00001-X (2011). 613 
35 Scheffer, I. E. et al. Epilepsy and mental retardation limited to females: an under-recognized 614 
disorder. Brain 131, 918-927, doi:10.1093/brain/awm338 (2008). 615 
36 Terracciano, A. et al. PCDH19-related epilepsy in two mosaic male patients. Epilepsia 57, e51-616 
55, doi:10.1111/epi.13295 (2016). 617 
37 Tinuper, P. et al. Definition and diagnostic criteria of sleep-related hypermotor epilepsy. 618 
Neurology 86, 1834-1842, doi:10.1212/WNL.0000000000002666 (2016). 619 
38 Hildebrand, M. S. et al. A targeted resequencing gene panel for focal epilepsy. Neurology 86, 620 
1605-1612, doi:10.1212/WNL.0000000000002608 (2016). 621 
 23
39 Poulat, A. L. et al. A proposed diagnostic approach for infantile spasms based on a spectrum of 622 
variable aetiology. European journal of paediatric neurology : EJPN : official journal of the 623 
European Paediatric Neurology Society 18, 176-182, doi:10.1016/j.ejpn.2013.11.005 (2014). 624 
40 Michaud, J. L. et al. The genetic landscape of infantile spasms. Hum Mol Genet 23, 4846-4858, 625 
doi:10.1093/hmg/ddu199 (2014). 626 
41 McCarthy, J. J. & Mendelsohn, B. A.     (2016). 627 
42 National Society of Genetic Counselors' Definition Task, F. et al. A new definition of Genetic 628 
Counseling: National Society of Genetic Counselors' Task Force report. Journal of genetic 629 
counseling 15, 77-83, doi:10.1007/s10897-005-9014-3 (2006). 630 
43 Gajecka, M. Unrevealed mosaicism in the next-generation sequencing era. Molecular genetics 631 
and genomics : MGG 291, 513-530, doi:10.1007/s00438-015-1130-7 (2016). 632 
44 National Institute for Health and Care Excellence. The Diagnosis and Management of the 633 
epilepsies in adults and children in primary and secondary care/cg137. (National, Institute for 634 
Health and Care Excellence, 2012). 635 
45 Berg, A. T. et al. Revised terminology and concepts for organization of seizures and epilepsies: 636 
report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 51, 637 
676-685, doi:EPI2522 [pii] 638 
10.1111/j.1528-1167.2010.02522.x (2010). 639 
46 Raza, A., Coomarasamy, A. & Khan, K. S. Best evidence continuous medical education. Arch 640 
Gynecol Obstet 280, 683-687, doi:10.1007/s00404-009-1128-7 (2009). 641 
47 Davis, D., Galbraith, R., American College of Chest Physicians, H. & Science Policy, C. 642 
Continuing medical education effect on practice performance: effectiveness of continuing 643 
medical education: American College of Chest Physicians Evidence-Based Educational 644 
Guidelines. Chest 135, 42S-48S, doi:10.1378/chest.08-2517 (2009). 645 
48 Bluestone, J. et al. Effective in-service training design and delivery: evidence from an 646 
integrative literature review. Hum Resour Health 11, 51, doi:10.1186/1478-4491-11-51 (2013). 647 
49 Schwarz, J. M., Cooper, D. N., Schuelke, M. & Seelow, D. MutationTaster2: mutation 648 
prediction for the deep-sequencing age. Nat Methods 11, 361-362, doi:10.1038/nmeth.2890 649 
(2014). 650 
 651 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  Demographics of patients for gene panel testing 
 
NEE – Neonatal Epileptic Encephalopathy (epilepsy with onset between birth and three months of 
age) 
IEE - Infantile Epileptic Encephalopathy (epilepsy with onset between four and 12 months) 
GEFS – Generalised Epilepsy with Febrile Seizures (https://www.epilepsydiagnosis.org/syndrome/fbp-
overview.html)  
TLE – Temporal Lobe Epilepsy (https://www.epilepsydiagnosis.org/syndrome/other-familial-temporal-
lobe-overview.html)  
NFLE – Nocturnal Frontal Lobe Epilepsy also known as SHE – Sleep-related Hypermotor Epilepsy 37 
LGS – Lennox-Gastaut syndrome (https://www.epilepsydiagnosis.org/syndrome/lgs-overview.html) 
 
 
Age at seizure onset Syndrome Number Age at testing
median years, (range) 
Neonatal (0-1 mo) NEE 14 3.75 (0.2-16.9)
 Benign neonatal 2 0.2 (0.2)
Infantile (2-24 mo) Infantile EE 19 7.5 (0.3-22.9)
 FS/TLE spectrum 4 6.1 (1.3-18.3)
 Infantile spasms 11 6.5 (0.5-12.2)
Childhood (>2y) NFLE/SHE 6 13.7 (5.6-17.6)
 Generalised (LGS-like) 9 15.1 (3.4-19.9)
 Early-onset absence 4 7.45 (1.4-14.7)
 Epilepsy-Aphasia spectrum 11 10.8 (7.3-17.2) 
 Familial focal epilepsy 8 10.45 (4.0-14.5)
 Refractory focal epilepsy 8 9 (4.4-17.4)
Total  96 7.5 (0.2-22.9)
Ion transport Neuro-
transmitter 
related 
Gene 
expression 
Scaffolding and 
Trafficking 
Intracellular 
Signalling 
Other Functions
ATP1A2 
ATP1A3 
CACNA1A 
CACNA1H 
CACNB4 
CLCN2* 
HCN1 
KCNA2 
KCNB1 
KCND2 
KCNH5 
KCNH8 
KCNMA1 
KCNQ2 
KCNQ3 
KCNQ5 
KCNT1 
KCTD7* 
LGI1 
SCN1A 
SCN1B 
SCN2A 
SCN8A 
SLC12A5 
SLC6A1 
SLC9A6 
CHRNA2 
CHRNA4 
CHRNB2 
GABBR1 
GABBR2 
GABRA1 
GABRA5 
GABRB3 
GABRD 
GABRG2  
GRIN1 
GRIN2A  
GRIN2B 
GRIN2D 
NRXN1 
PRRT2 
SLC1A2 
SLC25A22 
SYNGAP1 
ARX 
ATRX 
CHD2  
CUX2 
EEF1A2 
FOXG1 
HDAC4 
HNRNPU 
HUWE1 
MBD5* 
MECP2 
MEF2C 
PURA 
SMARCA2 
TCF4 
ZDHHC9 
 
CNKSR2 
DNM1 
IQSEC2 
KANK1 
KIAA2022 
PCDH19 
PIGA 
PIGO 
PIGT 
RELN 
SPTAN1 
STX1B 
STXBP1 
TBC1D24 
 
DEPDC5 
GNAO1 
MTOR 
NPRL2 
NPRL3 
PIK3R2 
PLCB1 
RYR3* 
SIK1 
 
ADSL 
ALDH7A1 
ALG13 
ARHGEF9 
CDKL5 
CPA6 
FASN 
GAMT 
GATM 
PIK3AP1  
PNKP 
PNPO  
POLG 
ST3GAL3 
SLC13A5 
SLC2A1 
SLC35A2 
SLC35A3 
SLC6A8 
SZT2 
UBE3A 
WWOX 
 
CHE-45, CHE-76 additions to CHE-45, CHE-85 additions to CHE-76, CHE-102 additions to CHE-85 
*Genes removed from CHE-102 
 
 
Table 2: Gene Panels used in this study, categorized by their function  
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 Patients with  
Age at seizure 
onset 
no variants 
only benign 
variants 
VUS 
pathogenic 
variants 
Total 
Diagnostic 
Yield 
0-1m 1 3 2 10 16 63%
2-24m 14 10 3 7 34 21%
  IEE 5 7 3 4 19 21%
  FS/TLE 2 0 0 2 4 50%
  IS 7 3 0 1 11 *9%
>2y 22 18 4 2 46 4%
  NFLE/SHE 4 2 0 0 6 0%
  GGE 4 3 2 0 9 0%
  EOABS 0 4 0 0 4 0%
  ESES 5 5 0 1 11 9%
  FFE 4 2 1 1 8 13%
  DRE-FOC 5 2 1 0 8 0%
Grand Total 37 31 9 19 96 20%
Table 5. Variant yield by age of onset and epilepsy syndrome 
* one further case was subsequently solved through whole genome research investigation  
 
 
 Clinicians’ Opinions 
Do you think that genetic testing.. Yes 
..helped you to confirm or refine an existing or suspected clinical diagnosis? 83% 
..has allowed a diagnosis to be made earlier than with clinical and EEG data alone? 83% 
..saved your patient from additional investigations? 50% 
..results altered your treatment and/or management approach? 67% 
..results prevented the prescription of drugs that could have worsened the epilepsy? 17% 
..was helpful in providing an explanation of the underlying disease for the family? 83% 
Families views 
Question Strongly/ 
Agree 
How helpful was genetic testing in giving you a cause for your child's Epilepsy? 70% 
Did the healthcare professionals give you enough opportunity to ask questions? 100% 
Did the healthcare professionals explain things in a way you could understand? 100% 
How helpful did you find it to attend the specialist outpatient clinic? 100% 
How likely are you to recommend our service to friends or family who need similar 
care? 
100% 
 
Table 6. Referring clinicians' opinions and families’ views of the epilepsy genetics service 
 
